Nanocarriers in Gene Therapy

Abstract

Getting nucleic acids into the right cells has always been the hardest part of gene therapy. Naked RNA or DNA injected into the bloodstream survives less than five minutes before nucleases chew it apart, and even if it reaches a cell intact, the negative charge on the backbone keeps it from crossing the membrane. Viral vectors solve these problems elegantly-- evolution has spent millions of years optimising them for exactly this task -- but they bring their own baggage: immunogenicity, limited cargo capacity, and manufacturing headaches that make scale-up expensive and slow. Lipid nanoparticles changed the equation. The approval of Onpattro for hereditary transthyretin amyloidosis in 2018, and then the breathtaking rollout of mRNA COVID vaccines in 2020-2021, proved that synthetic nanocarriers could deliver nucleic acid cargoes at clinical scale, safely and affordably. But the field is far from done. Onpattro and the vaccines both rely on the liver's natural appetite for lipid particles -- hepatocytes hoover up LNPs through the ApoE-LDLR pathway with remarkable efficiency. Getting LNPs to go anywhere else -- lungs, brain, tumours, muscle -- remains an unsolved problem, with extrahepatic delivery efficiencies typically below 5 percent of the injected dose. We set out to compare 180 nanocarrier gene therapy systems head to head: 54 lipid nanoparticle formulations, 48 polymer-based polyplexes, 36 inorganic nanoparticles, and 42 hybrid designs, all tested in our laboratories in Stockholm and Madrid between 2019 and 2023. We developed a Gene Therapy Nanocarrier Quality Index (GTNQI) that scores each system on five dimensions - how well it encapsulates the cargo, how much cargo escapes the endosome, whether it reaches the intended tissue, how much immune activation it triggers, and how long the therapeutic effect lasts. GTNQI correlated tightly with actual in vivo gene expression outcomes in mice (r = +0.84; AUC = 0.882 for predicting therapeutic-level expression lasting at least a week). The stand-out performers were SORT-targeted LNPs -- formulations containing an extra lipid component that redirects organ tropism away from the liver -- which achieved lung delivery rates nearly six times higher than standard LNPs and came closest to the tissue-specific gene therapy that the field has been chasing for two decades.